DK1045918T3 - G protein-relaterede kinasemutanter i essentiel hypertension - Google Patents

G protein-relaterede kinasemutanter i essentiel hypertension

Info

Publication number: DK1045918T3
Authority: DK; Denmark
Prior art keywords: essential hypertension; present; protein; related kinase; kinase mutants
Prior art date: 1998-01-12

Application number

DK99902201T

Other languages

Danish (da)

English (en)

Inventor

Robin Felder

Pedro Jose

Original Assignee

Pedro Jose

Felder Robin A

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-01-12

Filing date

1999-01-12

Publication date

2008-12-08

1999-01-12 Application filed by Pedro Jose, Felder Robin A filed Critical Pedro Jose

2008-12-08 Application granted granted Critical

2008-12-08 Publication of DK1045918T3 publication Critical patent/DK1045918T3/da

Links

208000007530 Essential hypertension Diseases 0.000 title abstract 3
108091006027 G proteins Proteins 0.000 title 1
102000030782 GTP binding Human genes 0.000 title 1
108091000058 GTP-Binding Proteins 0.000 title 1
108091000080 Phosphotransferase Proteins 0.000 title 1
102000020233 phosphotransferase Human genes 0.000 title 1
238000000034 method Methods 0.000 abstract 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
230000003276 anti-hypertensive effect Effects 0.000 abstract 1
229940030600 antihypertensive agent Drugs 0.000 abstract 1
239000002220 antihypertensive agent Substances 0.000 abstract 1
230000001413 cellular effect Effects 0.000 abstract 1
238000002405 diagnostic procedure Methods 0.000 abstract 1
238000007876 drug discovery Methods 0.000 abstract 1
230000002068 genetic effect Effects 0.000 abstract 1
210000003292 kidney cell Anatomy 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
238000012216 screening Methods 0.000 abstract 1
229910052708 sodium Inorganic materials 0.000 abstract 1
239000011734 sodium Substances 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/054—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function
- A01K2217/056—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function due to mutation of coding region of the transgene (dominant negative)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Cell Biology (AREA)
Molecular Biology (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)
Enzymes And Modification Thereof (AREA)

DK99902201T 1998-01-12 1999-01-12 G protein-relaterede kinasemutanter i essentiel hypertension DK1045918T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US7119998P	1998-01-12	1998-01-12
US9827998P	1998-08-28	1998-08-28
PCT/US1999/000663 WO1999035279A1 (fr)	1998-01-12	1999-01-12	Mutant de kinases apparentees a la proteine g contre l'hypertension essentielle

Publications (1)

Publication Number	Publication Date
DK1045918T3 true DK1045918T3 (da)	2008-12-08

Family

ID=26751950

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK99902201T DK1045918T3 (da)	1998-01-12	1999-01-12	G protein-relaterede kinasemutanter i essentiel hypertension

Country Status (9)

Country	Link
US (3)	US6660474B1 (fr)
EP (2)	EP2009109A1 (fr)
JP (2)	JP4652566B2 (fr)
AT (1)	ATE405661T1 (fr)
AU (1)	AU2223899A (fr)
CA (1)	CA2318479C (fr)
DE (1)	DE69939367D1 (fr)
DK (1)	DK1045918T3 (fr)
WO (1)	WO1999035279A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2002214681A1 (en) *	2000-10-31	2002-05-15	Duke University	Hypertension
WO2002103020A1 (fr) *	2001-06-15	2002-12-27	Takeda Chemical Industries, Ltd.	Nouveau gene associe a une maladie et son utilisation
AU2002358267A1 (en) *	2001-12-19	2003-07-09	Millennium Pharmaceuticals, Inc.	Methods and compositions in treating pain and painful disorders using 1465,1587, 2146, 2207, 32838, 336 and 52908
WO2005093096A1 (fr) *	2004-03-29	2005-10-06	Universitat Pompeu Fabra	Methode et materiel de detection du risque de presenter une hypertension
WO2005114195A1 (fr) *	2004-05-21	2005-12-01	Bayer Healthcare Ag	Diagnostic et therapeutique de pathologies en rapport avec la kinase 4 associee au recepteur couple une proteine g (grk4)
CN100465288C (zh) *	2005-08-10	2009-03-04	中国医学科学院阜外心血管病医院	检测与人类原发性高血压相关的grk4基因多态的方法
US20080268442A1 (en) *	2007-04-24	2008-10-30	Igd Intel, Llc	Method and system for preparing a blood sample for a disease association gene transcript test
US8135545B2 (en)	2007-11-09	2012-03-13	Iverson Genetic Diagnostics, Inc.	System and method for collecting data regarding broad-based neurotoxin-related gene mutation association
US20090125244A1 (en) *	2007-11-09	2009-05-14	Igd Intel Llc	Broad-based neurotoxin-related gene mutation association from a gene transcript test
US9784726B2 (en)	2013-01-08	2017-10-10	Atrogi Ab	Screening method, a kit, a method of treatment and a compound for use in a method of treatment
WO2014108531A1 (fr) *	2013-01-13	2014-07-17	Atrogi Ab	Procédé de criblage, kit, procédé de traitement et composé destiné à une utilisation dans un procédé de traitement
WO2015090350A1 (fr)	2013-12-16	2015-06-25	Atrogi Ab	Procédé de tamisage, kit, procédé de traitement et composé pour l'utilisation dans un procédé de traitement
CN105296488B (zh) *	2015-12-02	2018-05-01	中国人民解放军第三军医大学第三附属医院	超声微泡介导的siRNA干扰GRK4在靶向调节尿钠排泄及血压水平中的应用
GB201714734D0 (en)	2017-09-13	2017-10-25	Atrogi Ab	New compounds and uses
GB201714740D0 (en)	2017-09-13	2017-10-25	Atrogi Ab	New compounds and uses
GB201714736D0 (en)	2017-09-13	2017-10-25	Atrogi Ab	New compounds and uses
GB201714745D0 (en)	2017-09-13	2017-10-25	Atrogi Ab	New compounds and uses
CN107881226A (zh) *	2017-10-30	2018-04-06	广东药科大学	Scad基因或scad蛋白在制备防治血管重构和重大血管疾病药物中的应用
GB201903832D0 (en)	2019-03-20	2019-05-01	Atrogi Ab	New compounds and methods

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4873191A (en)	1981-06-12	1989-10-10	Ohio University	Genetic transformation of zygotes
US4736866B1 (en)	1984-06-22	1988-04-12		Transgenic non-human mammals
DE3854823T2 (de)	1987-05-01	1996-05-23	Stratagene Inc	Mutagenesetest durch Verwendung von nicht menschlichen Lebewesen, die Test-DNS-Sequenzen enthalten
US5221778A (en)	1988-08-24	1993-06-22	Yale University	Multiplex gene regulation
US5098890A (en)	1988-11-07	1992-03-24	Temple University-Of The Commonwealth System Of Higher Education	Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
US5175384A (en)	1988-12-05	1992-12-29	Genpharm International	Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5087617A (en)	1989-02-15	1992-02-11	Board Of Regents, The University Of Texas System	Methods and compositions for treatment of cancer using oligonucleotides
US5175383A (en)	1989-02-17	1992-12-29	President And Fellows Of Harvard College	Animal model for benign prostatic disease
US5464764A (en)	1989-08-22	1995-11-07	University Of Utah Research Foundation	Positive-negative selection methods and vectors
US5166195A (en)	1990-05-11	1992-11-24	Isis Pharmaceuticals, Inc.	Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
US5614396A (en)	1990-06-14	1997-03-25	Baylor College Of Medicine	Methods for the genetic modification of endogenous genes in animal cells by homologous recombination
US5387742A (en)	1990-06-15	1995-02-07	Scios Nova Inc.	Transgenic mice displaying the amyloid-forming pathology of alzheimer's disease
US5135917A (en)	1990-07-12	1992-08-04	Nova Pharmaceutical Corporation	Interleukin receptor expression inhibiting antisense oligonucleotides
US5288846A (en)	1990-10-19	1994-02-22	The General Hospital Corporation	Cell specific gene regulators
DE4126968A1 (de)	1991-08-14	1993-02-18	Detlev Prof Dr Med Ganten	Transgene ratten, die in ihrem genom mindestens ein menschliches gen enthalten, das an der blutdruckregulation beteiligt ist
US5298422A (en)	1991-11-06	1994-03-29	Baylor College Of Medicine	Myogenic vector systems
EP0620849B1 (fr)	1992-01-07	2003-06-25	Elan Pharmaceuticals, Inc.	Modeles d'animaux transgeniques utilises pour tester des traitements potentiels relatifs a la maladie d'alzheimer
EP0663952A4 (fr)	1992-09-11	1997-06-11	Univ California	Animaux transgeniques possedant des genes de transduction lymphocytaire cibles.
CA2151585A1 (fr)	1992-12-14	1994-06-23	Start Technology Partnership	Administration d'oligonucleotides antisens de l'arnm des recepteurs de la dopamine pour le diagnostic et le traitement des affections neurologiques
WO1994023049A2 (fr)	1993-04-02	1994-10-13	The Johns Hopkins University	Introduction et expression de grandes sequences genomiques chez des animaux transgeniques
US6664107B1 (en)	1993-05-26	2003-12-16	Ontario Cancer Institute, University Health Network	CD45 disrupted nucleic acid
US5856103A (en)	1994-10-07	1999-01-05	Board Of Regents The University Of Texas	Method for selectively ranking sequences for antisense targeting
US5783683A (en)	1995-01-10	1998-07-21	Genta Inc.	Antisense oligonucleotides which reduce expression of the FGFRI gene
US5968770A (en)	1995-02-10	1999-10-19	Millennium Pharmaceuticals, Inc.	Compositions and methods for the treatment and diagnosis of cardiovascular disease using rchd523 as a target
NO953680D0 (no)	1995-09-18	1995-09-18	Hans Prydz	Cellesyklusenzymer
CA2236825A1 (fr)	1995-11-21	1997-05-29	Icn Pharmaceuticals, Inc.	Inhibition de la croissance tumorale par des oligonucleotides antisens pour l'il-8 et le recepteur de l'il-8
US5856099A (en)	1996-05-21	1999-01-05	Isis Pharmaceuticals, Inc.	Antisense compositions and methods for modulating type I interleukin-1 receptor expression

1999
- 1999-01-12 EP EP08162553A patent/EP2009109A1/fr not_active Withdrawn
- 1999-01-12 EP EP99902201A patent/EP1045918B1/fr not_active Expired - Lifetime
- 1999-01-12 CA CA002318479A patent/CA2318479C/fr not_active Expired - Fee Related
- 1999-01-12 WO PCT/US1999/000663 patent/WO1999035279A1/fr not_active Ceased
- 1999-01-12 JP JP2000527662A patent/JP4652566B2/ja not_active Expired - Fee Related
- 1999-01-12 DE DE69939367T patent/DE69939367D1/de not_active Expired - Lifetime
- 1999-01-12 DK DK99902201T patent/DK1045918T3/da active
- 1999-01-12 AU AU22238/99A patent/AU2223899A/en not_active Abandoned
- 1999-01-12 AT AT99902201T patent/ATE405661T1/de not_active IP Right Cessation
2000
- 2000-07-12 US US09/614,748 patent/US6660474B1/en not_active Expired - Lifetime
2003
- 2003-10-02 US US10/677,983 patent/US20050089871A1/en not_active Abandoned
2008
- 2008-12-01 US US12/315,338 patent/US9074016B2/en not_active Expired - Fee Related
2010
- 2010-09-06 JP JP2010199161A patent/JP5340242B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP2009109A1 (fr)	2008-12-31
ATE405661T1 (de)	2008-09-15
JP4652566B2 (ja)	2011-03-16
DE69939367D1 (de)	2008-10-02
EP1045918A1 (fr)	2000-10-25
EP1045918B1 (fr)	2008-08-20
US9074016B2 (en)	2015-07-07
JP2002508157A (ja)	2002-03-19
US6660474B1 (en)	2003-12-09
JP5340242B2 (ja)	2013-11-13
CA2318479A1 (fr)	1999-07-15
WO1999035279A1 (fr)	1999-07-15
EP1045918A4 (fr)	2003-10-08
JP2011036253A (ja)	2011-02-24
AU2223899A (en)	1999-07-26
US20100313286A1 (en)	2010-12-09
US20050089871A1 (en)	2005-04-28
CA2318479C (fr)	2009-03-24

Publication	Publication Date	Title
DK1045918T3 (da)	2008-12-08	G protein-relaterede kinasemutanter i essentiel hypertension
CR7925A (es)	2006-02-06	Tinturas de cianina hidrofilicas, reactivas con tiol y conjugados de las mismas con biomoleculas para diagnostico por fluorescencia
DE60040677D1 (de)	2008-12-11	Verbessertes toxizität-screening verfahren
DE60005787D1 (de)	2003-11-13	Wasserlösliche rhodaminfarbstoffe und ihre konjugate
Telford et al.	2005	DPSS yellow‐green 561‐nm lasers for improved fluorochrome detection by flow cytometry
DE69942459D1 (de)	2010-07-15	Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
DK1290444T3 (da)	2010-01-18	Toxicitetstypisering under anvendelse af lever-stamceller
ATE37375T1 (de)	1988-10-15	Phosphonyl-hydroxyacyl-aminosaeure-derivate und ihre verwendung als antihypertensiva.
CY1111006T1 (el)	2015-06-11	Εκριμματαση ασθενειας alzheimer
ATE273956T1 (de)	2004-09-15	Arylsubstituierte olefinische amine und ihre verwendung als cholinergische rezeptoragonisten
WO2005107491A3 (fr)	2005-12-22	Chromatographie d'affinite multi-lectine et ses utilisations
CA2439222A1 (fr)	2001-08-30	Procede permettant d'identifier des agonistes partiels du recepteur a2a
DE69828080D1 (de)	2005-01-13	Pyrimidinderivate als markierte bindungspartner
BRPI0412716A (pt)	2006-09-26	antagonistas de receptor muscarìnico de acetilcolina
BRPI0412679A (pt)	2006-10-03	antagonistas de receptor muscarìnico de acetilcolina
DE60322748D1 (de)	2008-09-18	Xanthinderivate als a2b-adenosinrezeptorantagonisten
NO331018B1 (no)	2011-09-12	In vitro fremgangsmate ved bestemmelse av pre-neoplastiske og/eller neoplastiske tilstander hos pattedyr ved purinergisk reseptorekspresjon, samt anvendelse og sett for slik pavisning
MEP56408A (en)	2011-05-10	Conjugates and methods for the production thereof, and their use for transporting molecules via biological membranes
EP1265640A4 (fr)	2003-07-09	Sondes intercalaires a membrane fluorescente et procedes d'utilisation de ces dernieres
ES2185002T3 (es)	2003-04-16	Metodos y composiciones para detectar mutaciones por empalme de la deshidrogenasa de dihidro-pirimidina.
NO20002408L (no)	2000-07-12	5-HT1F antagonister
DE69626680D1 (de)	2003-04-17	Kondensierte isoindolone als proteinkinase c inhibitoren
WO2004063339A3 (fr)	2005-07-21	Essai de liaison de g-quadruplex et composes utilises a cette fin
ATE434936T1 (de)	2009-07-15	Tsg101-gag-wechselwirkung und ihre verwendung
DE69737329D1 (de)	2007-03-22	Synthetische biepitopische zusammensetzungen zur verwendung als kalibratoren bei der biologischen bestimmung von troponin i